We report the case of a young patient treated with rituximab-containing chemotherapy who was infected with measles despite previous vaccination. Treatment with vitamin A, ribavirin, and immunoglobulins was started; nevertheless he developed severe pneumonitis and deceased. Broad vaccination coverage is crucial in protecting vulnerable subjects.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209686 | PMC |
| http://dx.doi.org/10.1093/ofid/ofy244 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Survival analysis of a 16-year cohort of follicular lymphoma patients receiving systemic treatment in Brazil.
Front Pharmacol
January 2025
Department of Social Pharmacy, Federal University of Minas Gerais, Belo Horizonte, Brazil.
Introduction: Follicular lymphoma (FL) is a common type of non-Hodgkin lymphoma that is incurable but often follows an indolent course. While survival is improving thanks to advances in diagnosis, supportive care, and new therapies, understanding outcomes and their impact on overall survival is still limited. There are few studies on FL in Brazil, so this study aims to evaluate the patient's profile, morbidity and mortality treated by the Brazilian national health service (SUS) and evaluate risk factors associated with treatment failure.
View Article and Find Full Text PDF[Prognostic impact of early initiation of chemotherapy after brain biopsy in primary central nervous system lymphoma].
Rinsho Ketsueki
November 2024
Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo.
Primary central nervous system lymphoma (PCNSL) is a B-cell lymphoma confined to the CNS. In general, early initiation of treatment after diagnosis is considered to be associated with improved prognosis in patients with malignancy. However, the prognostic impact of the time from diagnostic brain biopsy to initiation of treatment in patients with PCNSL remains unclear.
View Article and Find Full Text PDFLong-Term Recurrence-Free Survival of an Elderly Patient With Diffuse Large B-cell Lymphoma in the Setting of Rituximab-Containing Therapy and a Natural History of Gastric Adenocarcinoma.
Cureus
August 2024
Department of Internal Medicine, Sapporo Shirakaba-dai Hospital, Sapporo, JPN.
Article Synopsis
- - The case involves a 97-year-old woman with both gastric cancer and diffuse large B-cell lymphoma (DLBCL), who maintained remission from DLBCL for 10 years after receiving minimal chemotherapy with rituximab.
- - Despite the initial success, she experienced severe side effects, leading her to refuse further treatment for her cancers.
- - Ten years later, she developed multiple new tumors in various organs, which were found to be adenocarcinoma (not lymphoma) after her passing, highlighting the complexities of treating DLBCL and gastric cancer in elderly patients.
Mycoplasma hominis as Cause of Extragenital Infection in Patients with Hypogammaglobulinemia: Report of 2 Cases and Literature Review.
Infect Dis Ther
October 2024
Division of Infectious Diseases, Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy.
Mycoplasma hominis can be a part of human urogenital tract microbiome, and it is a frequent cause of urogenital infections. In rare cases, it can also cause extragenital infections, especially in immunocompromised patients. In this case series, we report two cases and provide a literature review of extragenital infections caused by M.
View Article and Find Full Text PDFImpact of debulking therapy on the clinical outcomes of axicabtagene ciloleucel in the treatment of relapsed or refractory large B-cell lymphoma.
Am J Cancer Res
June 2024
Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg Würzburg, Germany.
Axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor T-cell therapy, was approved for relapsed/refractory (R/R) large B-cell lymphoma (LBCL) based on the results from pivotal Cohorts 1+2 of ZUMA-1 (NCT02348216). ZUMA-1 was expanded to investigate safety management strategies aimed at reducing the incidence and severity of cytokine release syndrome (CRS) and neurologic events (NEs). Prospective safety expansion Cohort 5 evaluated the impact of debulking therapy, including rituximab-containing immunochemotherapy regimens and radiotherapy, in axi-cel-treated patients; the CRS and NE management strategy paralleled those in Cohorts 1+2.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!